It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

RFK Jr.'s comments about the gene-editing technology raise a question about how he would regulate it as head of HHS.

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science Foundation’s Faculty Early Career Development Program (CAREER) for ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field’s most competitive ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

As translational CRISPR-based research continues to make waves in laboratories and the clinic, scientists across life science disciplines pursue out-of-the-ordinary genome editing applications. From ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.